Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

ClinicalTrials.gov ID: NCT02175771

Public ClinicalTrials.gov record NCT02175771. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of the study is to evaluate the long-term safety of fluticasone propionate (Fp) inhalation powder in 2 strengths and fluticasone propionate/salmeterol inhalation (FS) powder in 2 strengths when administered with the Teva multidose dry powder inhaler (MDPI) device over 26 weeks in patients with persistent asthma.

Study identification

NCT ID
NCT02175771
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
758 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2014
Primary completion
Jun 30, 2015
Completion
Jun 30, 2015
Last update posted
Nov 8, 2021

2014 – 2015

United States locations

U.S. sites
101
U.S. states
35
U.S. cities
88
Facility City State ZIP Site status
Teva Investigational Site 12068 Birmingham Alabama
Teva Investigational Site 12112 Mobile Alabama
Teva Investigational Site 12130 Pell City Alabama
Teva Investigational Site 12119 Little Rock Alaska
Teva Investigational Site 12076 Phoenix Arizona
Teva Investigational Site 12135 Scottsdale Arizona
Teva Investigational Site 12132 Tucson Arizona
Teva Investigational Site 12102 Fountain Valley California
Teva Investigational Site 12104 Fresno California
Teva Investigational Site 12123 Fullerton California
Teva Investigational Site 12103 Huntington Beach California
Teva Investigational Site 12073 Long Beach California
Teva Investigational Site 12077 Mission Viejo California
Teva Investigational Site 12098 Napa California
Teva Investigational Site 12149 Northridge California
Teva Investigational Site 12081 Orange California
Teva Investigational Site 12100 Rancho Mirage California
Teva Investigational Site 12133 Riverside California
Teva Investigational Site 12146 Riverside California
Teva Investigational Site 12075 Rolling Hills Estates California
Teva Investigational Site 12074 San Diego California
Teva Investigational Site 12150 San Diego California
Teva Investigational Site 12064 San Jose California
Teva Investigational Site 12061 Stockton California
Teva Investigational Site 12141 Walnut Creek California
Teva Investigational Site 12043 Denver Colorado
Teva Investigational Site 12051 Denver Colorado
Teva Investigational Site 12091 Waterbury Connecticut
Teva Investigational Site 12078 Fort Lauderdale Florida
Teva Investigational Site 12140 Hialeah Florida
Teva Investigational Site 12066 Kissimmee Florida
Teva Investigational Site 12120 Miami Florida
Teva Investigational Site 12127 Miami Florida
Teva Investigational Site 12148 Miami Florida
Teva Investigational Site 12114 Ocala Florida
Teva Investigational Site 12055 Sarasota Florida
Teva Investigational Site 12048 Tallahassee Florida
Teva Investigational Site 12122 Tamarac Florida
Teva Investigational Site 12086 Winter Park Florida
Teva Investigational Site 12111 Gainesville Georgia
Teva Investigational Site 12070 Lawrenceville Georgia
Teva Investigational Site 12072 Marietta Georgia
Teva Investigational Site 12106 Coeur d'Alene Idaho
Teva Investigational Site 12117 Eagle Idaho
Teva Investigational Site 12065 River Forest Illinois
Teva Investigational Site 12059 Shiloh Illinois
Teva Investigational Site 12056 Overland Park Kansas
Teva Investigational Site 12138 Fort Mitchell Kentucky
Teva Investigational Site 12092 Owensboro Kentucky
Teva Investigational Site 12087 Covington Louisiana
Teva Investigational Site 12095 Bangor Maine
Teva Investigational Site 12042 Baltimore Maryland
Teva Investigational Site 12124 Baltimore Maryland
Teva Investigational Site 12052 North Dartmouth Massachusetts
Teva Investigational Site 12139 Minneapolis Minnesota
Teva Investigational Site 12137 Plymouth Minnesota
Teva Investigational Site 12079 Columbia Missouri
Teva Investigational Site 12067 Rolla Missouri
Teva Investigational Site 12057 St Louis Missouri
Teva Investigational Site 12060 St Louis Missouri
Teva Investigational Site 12108 St Louis Missouri
Teva Investigational Site 12128 Warrensburg Missouri
Teva Investigational Site 12136 Bellevue Nebraska
Teva Investigational Site 12115 Las Vegas Nevada
Teva Investigational Site 12131 Las Vegas Nevada
Teva Investigational Site 12126 Ocean City New Jersey
Teva Investigational Site 12129 Verona New Jersey
Teva Investigational Site 12058 Rochester New York
Teva Investigational Site 12113 Rockville Centre New York
Teva Investigational Site 12047 Charlotte North Carolina
Teva Investigational Site 12085 Charlotte North Carolina
Teva Investigational Site 12144 Winston-Salem North Carolina
Teva Investigational Site 12053 Canton Ohio
Teva Investigational Site 12094 Cincinnati Ohio
Teva Investigational Site 12105 Cincinnati Ohio
Teva Investigational Site 12107 Sylvania Ohio
Teva Investigational Site 12069 Tiffin Ohio
Teva Investigational Site 12045 Oklahoma City Oklahoma
Teva Investigational Site 12080 Oklahoma City Oklahoma
Teva Investigational Site 12083 Oklahoma City Oklahoma
Teva Investigational Site 12062 Eugene Oregon
Teva Investigational Site 12097 Medford Oregon
Teva Investigational Site 12049 Portland Oregon
Teva Investigational Site 12134 Bryn Mawr Pennsylvania
Teva Investigational Site 12090 Philadelphia Pennsylvania
Teva Investigational Site 12089 Providence Rhode Island
Teva Investigational Site 12088 Warwick Rhode Island
Teva Investigational Site 12096 Charleston South Carolina
Teva Investigational Site 12147 Spartanburg South Carolina
Teva Investigational Site 12121 Dallas Texas
Teva Investigational Site 12099 El Paso Texas
Teva Investigational Site 12071 Live Oak Texas
Teva Investigational Site 12054 San Antonio Texas
Teva Investigational Site 12145 Waco Texas
Teva Investigational Site 12046 Murray Utah
Teva Investigational Site 12041 South Burlington Vermont
Teva Investigational Site 12125 Richmond Virginia
Teva Investigational Site 12101 Seattle Washington
Teva Investigational Site 12109 Spokane Washington
Teva Investigational Site 12044 Tacoma Washington
Teva Investigational Site 12082 Greenfield Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Persistent Asthma trials

Other public records listing Persistent Asthma. Sorted by last update posted; newest first. Not a recommendation.

All Persistent Asthma trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02175771, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02175771 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →